Abstract: Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.

Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human serine/threonine protein phosphatases and which are capable of inhibiting protein phosphatase expression. Methods of inhibiting the expression of human protein serine/threonine phosphatases using oligonucleotides of the invention are also provided. The present invention further comprises methods of preventing or inhibiting hyperproliferation of cells and methods of treating abnormal conditions, including cancer, using oligonucleotides of the invention.

Abstract: The present invention provides, inter alia, methods of selecting a single-stranded oligomeric compounds for inhibiting RNA expression, methods of generating double-stranded oligomeric compounds, methods of identifying optimized double-stranded oligomeric compounds, methods of selecting optimized single-stranded oligomeric compounds, methods of selecting optimized double-stranded oligomeric compounds, methods of identifying multifunctional oligomeric compounds, methods for optimizing target region selection for modulation of RNA expression, methods of optimizing expression modulation of RNA, and the like. The present invention further provides oligomeric compounds, 8-80 nucleobases in length targeted to a target RNA, wherein said oligomeric compound hybridizes to said target RNA and inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms, and multifunctional oligomeric compounds.

Abstract: Compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding thyroid hormone receptor interactor 3. Methods of using these compounds for modulation of thyroid hormone receptor interactor 3 expression and for diagnosis and treatment of disease associated with expression of thyroid hormone receptor interactor 3 are provided.

Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor a are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of MAGE-D1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding MAGE-D1. Methods of using these compounds for modulation of MAGE-D1 expression and for diagnosis and treatment of disease associated with expression of MAGE-D1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of AP-2 alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding AP-2 alpha. Methods of using these compounds for modulation of AP-2 alpha expression and for diagnosis and treatment of disease associated with expression of AP-2 alpha are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of MALT1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding MALT1. Methods of using these compounds for modulation of MALT1 expression and for diagnosis and treatment of disease associated with expression of MALT1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of EMAP-II. The compositions comprise oligonucleotides, targeted to nucleic acid encoding EMAP-II. Methods of using these compounds for modulation of EMAP-II expression and for diagnosis and treatment of disease associated with expression of EMAP-II are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ADAM15. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ADAM15. Methods of using these compounds for modulation of ADAM15 expression and for diagnosis and treatment of disease associated with expression of ADAM15 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of jagged 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding jagged 1. Methods of using these compounds for modulation of jagged 1 expression and for diagnosis and treatment of disease associated with expression of jagged 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Gankyrin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Gankyrin. Methods of using these compounds for modulation of Gankyrin expression and for diagnosis and treatment of disease associated with expression of Gankyrin are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of BCL2-associated athanogene 5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding BCL2-associated athanogene 5. Methods of using these compounds for modulation of BCL2-associated athanogene 5 expression and for diagnosis and treatment of disease associated with expression of BCL2-associated athanogene 5 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of hepatocyte growth factor receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hepatocyte growth factor receptor. Methods of using these compounds for modulation of hepatocyte growth factor receptor expression and for diagnosis and treatment of disease associated with expression of hepatocyte growth factor receptor are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of squalene synthase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding squalene synthase. Methods of using these compounds for modulation of squalene synthase expression and for diagnosis and treatment of disease associated with expression of squalene synthase are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of huntingtin interacting protein 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding huntingtin interacting protein 2. Methods of using these compounds for modulation of huntingtin interacting protein 2 expression and for diagnosis and treatment of disease associated with expression of huntingtin interacting protein 2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of heat shock protein 90-alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding heat shock protein 90-alpha. Methods of using these compounds for modulation of heat shock protein 90-alpha expression and for diagnosis and treatment of disease associated with expression of heat shock protein 90-alpha are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of PPM1B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PPM1B. Methods of using these compounds for modulation of PPM1B expression and for diagnosis and treatment of disease associated with expression of PPM1B are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of c-src tyrosine kinase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding c-src tyrosine kinase. Methods of using these compounds for modulation of c-src tyrosine kinase expression and for diagnosis and treatment of disease associated with expression of c-src tyrosine kinase are provided.